Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse

Neurobiology of Disease

Volumn 81, Issue , 2015, Pages 168-175

  Lei, Peng ^a   Ayton, Scott ^a   Appukuttan, Ambili Thoppuvalappil ^a   Volitakis, Irene ^a   Adlard, Paul A ^a   Finkelstein, David I ^a   Bush, Ashley I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease; Clioquinol; Iron; Parkinson's disease; Tau

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CLIOQUINOL; IRON; TYROSINE 3 MONOOXYGENASE; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; METAL; TAU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PARKINSONISM; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; BRAIN; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; MAZE TEST; METABOLISM; MOTOR ACTIVITY; MUSCLE STRENGTH; NERVE CELL; PARKINSONIAN DISORDERS; PATHOLOGY; ROTAROD TEST; SUBSTANTIA NIGRA;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BRAIN; CLIOQUINOL; DEMENTIA; DISEASE MODELS, ANIMAL; DOPAMINE; MAZE LEARNING; METALS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; MUSCLE STRENGTH; NEURONS; PARKINSONIAN DISORDERS; ROTAROD PERFORMANCE TEST; SUBSTANTIA NIGRA; TAU PROTEINS; TYROSINE 3-MONOOXYGENASE;

EID: 84936987315     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.03.015     Document Type: Article

References (61)

1. Adlard P.A., Cherny R.A., Finkelstein D.I., Gautier E., Robb E., Cortes M., et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008, 59(1):43-55.
2. Adlard P.A., Sedjahtera A., Gunawan L., Bray L., Hare D., Lear J., et al. A novel approach to rapidly prevent age-related cognitive decline. Aging Cell 2014, 13(2):351-359.
3. Adlard P.A., Parncutt J., Lal V., James S., Hare D., Doble P., et al. Metal chaperones prevent zinc-mediated cognitive decline. Neurobiol. Dis. 2015, 81:196-202.
4. Arima K., Hirai S., Sunohara N., Aoto K., Izumiyama Y., Uéda K., et al. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res. 1999, 843(1-2):53-61.
5. Asao M. Clioquinol and S.M.O.N.: reanalysis of original data. Lancet 1979, 1(8113):446.
6. Ayton S., Lei P., Bush A.I. Metallostasis in Alzheimer's disease. Free Radic. Biol. Med. 2013, 62:76-89.
7. Ayton S., Lei P., Duce J.A., Wong B.X., Sedjahtera A., Adlard P.A., et al. Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann. Neurol. 2013, 73(4):554-559.
8. Ayton S., Lei P., Bush A.I. Biometals and their therapeutic implications in Alzheimer's disease. Neurotherapeutics 2015, 12(1):109-120.
9. Ayton S., Lei P., et al. Parkinson's disease iron deposition caused by nitric oxide-induced loss of beta-amyloid precursor protein. J. Neurosci. 2015, 35(8):3591-3597.
10. Bar-Am O., Amit T., Kupershmidt L., Aluf Y., Mechlovich D., Kabha H., et al. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging. Neurobiol. Aging 2015, 36(3):1529-1542.
11. Beard J.L., Killick T., Gonzales E., Bianco L. Reductions in the labile iron pool activate PKC and alter monoamine metabolism. FASEB J. 2006, 20(4):A193-A193.
12. Ben-Shachar D., Eshel G., Finberg J.P., Youdim M.B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 1991, 56(4):1441-1444.
13. Chen D., Cui Q.C., Yang H., Barrea R.A., Sarkar F.H., Sheng S., et al. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res. 2007, 67(4):1636-1644.
14. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30(3):665-676.
15. Crapper McLachlan D.R., Dalton A.J., Kruck T.P., Bell M.Y., Smith W.L., Kalow W., et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991, 337(8753):1304-1308.
16. Dawson H.N., Ferreira A., Eyster M.V., Ghoshal N., Binder L.I., Vitek M.P. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J. Cell Sci. 2001, 114:1179-1187.
17. Devos D., Moreau C., Devedjian J.C., Kluza J., Petrault M., Laloux C., et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid. Redox Signal. 2014, 21(2):195-210.
18. Ding W.Q., Yu H.J., Lind S.E. Zinc-binding compounds induce cancer cell death via distinct modes of action. Cancer Lett. 2008, 271(2):251-259.
19. Doody R.S., Raman R., Farlow M., Iwatsubo T., Vellas B., Joffe S., et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N. Engl. J. Med. 2013, 369(4):341-350.
20. Doody R.S., Thomas R.G., Farlow M., Iwatsubo T., Vellas B., Joffe S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 2014, 370(4):311-321.
21. Duce J.A., Tsatsanis A., Cater M.A., James S.A., Robb E., Wikhe K., et al. Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 2010, 142(6):857-867.
22. Dunkley P.R., Bobrovskaya L., Graham M.E., von Nagy-Felsobuki E.I., Dickson P.W. Tyrosine hydroxylase phosphorylation: regulation and consequences. J. Neurochem. 2004, 91(5):1025-1043.
23. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112(2):257-269.
24. Faux N.G., Ritchie C.W., Gunn A.P., Rembach A., Tsatsanis A., Bedo J., et al. PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses. J. Alzheimers Dis. 2010, 20(2):509-516.
25. Gal S., Zheng H., Fridkin M., Youdim M.B. Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox. Res. 2010, 17(1):15-27.
26. Gheyara A.L., Ponnusamy R., Djukic B., Craft R.J., Ho K., Guo W., et al. Tau reduction prevents disease in a mouse model of Dravet syndrome. Ann. Neurol. 2014, 76(3):443-456.
27. Gozes I. Tau pathology and future therapeutics. Curr. Alzheimer Res. 2010, 7(8):685-696.
28. Guo C., Wang P., Zhong M.L., Wang T., Huang X.S., Li J.Y., et al. Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. Neurochem. Int. 2013, 62(2):165-172.
29. Guo C., Wang T., Zheng W., Shan Z.Y., Teng W.P., Wang Z.Y. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 2013, 34(2):562-575.
30. Hare D., Ayton S., Bush A., Lei P. A delicate balance: iron metabolism and diseases of the brain. Front. Aging Neurosci. 2013, 5:34.
31. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003, 37(6):899-909.
32. Kaur D., Rajagopalan S., Andersen J.K. Chronic expression of H-ferritin in dopaminergic midbrain neurons results in an age-related expansion of the labile iron pool and subsequent neurodegeneration: implications for Parkinson's disease. Brain Res. 2009, 1297:17-22.
33. Kosik K.S., Crandall J.E., Mufson E.J., Neve R.L. Tau in situ hybridization in normal and Alzheimer brain: localization in the somatodendritic compartment. Ann. Neurol. 1989, 26(3):352-361.
34. Kupershmidt L., Weinreb O., Amit T., Mandel S., Bar-Am O., Youdim M.B. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience 2011, 189:345-358.
35. Kupershmidt L., Amit T., Bar-Am O., Youdim M.B., Weinreb O. The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. Antioxid. Redox Signal. 2012, 17(6):860-877.
36. Lannfelt L., Blennow K., Zetterberg H., Batsman S., Ames D., Harrison J., et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008, 7(9):779-786.
37. Lei P., Ayton S., Finkelstein D.I., Adlard P.A., Masters C.L., Bush A.I. Tau protein: relevance to Parkinson's disease. Int. J. Biochem. Cell Biol. 2010, 42(11):1775-1778.
38. Lei P., Ayton S., Finkelstein D.I., Spoerri L., Ciccotosto G.D., Wright D.K., et al. Tau deficiency induces Parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 2012, 18(2):291-295.
39. Lei P., Ayton S., Moon S., Zhang Q., Volitakis I., Finkelstein D.I., et al. Motor and cognitive deficits in aged tau knockout mice in two background strains. Mol. Neurodegener. 2014, 9(1):29.
40. Li C., Wang J., Zhou B. The metal chelating and chaperoning effects of clioquinol: insights from yeast studies. J. Alzheimers Dis. 2010, 21(4):1249-1262.
41. Ma Q.L., Zuo X., Yang F., Ubeda O.J., Gant D.J., Alaverdyan M., et al. Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging. J. Neurosci. 2014, 34(21):7124-7136.
42. Morris M., Maeda S., Vossel K.A., Mucke L. The many faces of tau. Neuron 2011, 70(3):410-426.
43. Morris M., Hamto P., Adame A., Devidze N., Masliah E., Mucke L. Age-appropriate cognition and subtle dopamine-independent motor deficits in aged Tau knockout mice. Neurobiol. Aging 2013, 34(6):1523-1529.
44. Nakae K., Yamamoto S., Igata A. Subacute myelo-optico-neuropathy (S.M.O.N.) in Japan. A community survey. Lancet 1971, 2(7723):510-512.
45. Nalls M.A., Pankratz N., Lill C.M., Do C.B., Hernandez D.G., Saad M., et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 2014, 46(9):989-993.
46. Nguyen T., Hamby A., Massa S.M. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(33):11840-11845.
47. Paylor R., Spencer C.M., Yuva-Paylor L.A., Pieke-Dahl S. The use of behavioral test batteries, II: effect of test interval. Physiol. Behav. 2006, 87(1):95-102.
48. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 2003, 60(12):1685-1691.
49. Salloway S., Sperling R., Fox N.C., Blennow K., Klunk W., Raskind M., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 2014, 370(4):322-333.
50. Salvatore M.F., Zhang J.L., Large D.M., Wilson P.E., Gash C.R., Thomas T.C., et al. Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra. J. Neurochem. 2004, 90(1):245-254.
51. Tardiff D.F., Tucci M.L., Caldwell K.A., Caldwell G.A., Lindquist S. Different 8-hydroxyquinolines protect models of TDP-43 protein, alpha-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J. Biol. Chem. 2012, 287(6):4107-4120.
52. Wang Y., Branicky R., Stepanyan Z., Carroll M., Guimond M.-P., Hihi A., et al. The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1. J. Biol. Chem. 2009, 284(1):314-323.
53. Wong B.X., Tsatsanis A., Lim L.Q., Adlard P.A., Bush A.I., Duce J.A. beta-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin. PLoS ONE 2014, 9(12):e114174.
54. Wong B.X., Ayton S., Lam L.Q., Lei P., Adlard P.A., Bush A.I., et al. A comparison of ceruloplasmin to biological polyanions in promoting the oxidation of Fe under physiologically relevant conditions. Biochim. Biophys. Acta 2014, 1840(12):3299-3310.
55. Yabuki Y., Ohizumi Y., Yokosuka A., Mimaki Y., Fukunaga K. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice. Neuroscience 2014, 259:126-141.
56. Yu H., Zhou Y., Lind S.E., Ding W.Q. Clioquinol targets zinc to lysosomes in human cancer cells. Biochem. J. 2009, 417(1):133-139.
57. Zheng H., Gal S., Weiner L.M., Bar-Am O., Warshawsky A., Fridkin M., et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 2005, 95(1):68-78.
58. Zheng H., Weiner L.M., Bar-Am O., Epsztejn S., Cabantchik Z.I., Warshawsky A., et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem. 2005, 13(3):773-783.
59. Zhu W., Xie W., Pan T., Xu P., Fridkin M., Zheng H., et al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 2007, 21(14):3835-3844.
60. Zhu W., Li X., Xie W., Luo F., Kaur D., Andersen J.K., et al. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Neurobiol. Dis. 2010, 37(2):307-313.
61. Zhukareva V., Vogelsberg-Ragaglia V., Van Deerlin V.M., Bruce J., Shuck T., Grossman M., et al. Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann. Neurol. 2001, 49(2):165-175.